nach oben

Erschienen in:

01.09.2014 | Original

Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients

verfasst von: Jan J. De Waele, J. Lipman, M. Akova, M. Bassetti, G. Dimopoulos, M. Kaukonen, D. Koulenti, C. Martin, P. Montravers, J. Rello, A. Rhodes, A. A. Udy, T. Starr, S. C. Wallis, J. A. Roberts

Erschienen in: Intensive Care Medicine | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Risk factors for β-lactam antibiotic underdosing in critically ill patients have not been described in large-scale studies. The objective of this study was to describe pharmacokinetic/pharmacodynamic (PK/PD) target non-attainment envisioning empirical dosing in critically ill patients and considering a worst-case scenario as well as to identify patient characteristics that are associated with target non-attainment.

Methods

This analysis uses data from the DALI study, a prospective, multi-centre pharmacokinetic point-prevalence study. For this analysis, we assumed that these were the concentrations that would be reached during empirical dosing, and calculated target attainment using a hypothetical target minimum inhibitory concentration (MIC), namely the susceptibility breakpoint of the least susceptible organism for which that antibiotic is commonly used. PK/PD targets were free drug concentration maintained above the MIC of the suspected pathogen for at least 50 % and 100 % of the dosing interval respectively (50 % and 100 % f T _>MIC). Multivariable analysis was performed to identify factors associated with inadequate antibiotic exposure.

Results

A total of 343 critically ill patients receiving eight different β-lactam antibiotics were included. The median (interquartile range) age was 60 (47–73) years, APACHE II score was 18 (13–24). In the hypothetical situation of empirical dosing, antibiotic concentrations remained below the MIC during 50 % and 100 % of the dosing interval in 66 (19.2 %) and 142 (41.4 %) patients respectively. The use of intermittent infusion was significantly associated with increased risk of non-attainment for both targets; creatinine clearance was independently associated with not reaching the 100 % f T _>MIC target.

Conclusions

This study found that—in empirical dosing and considering a worst-case scenario—19 % and 41 % of the patients would not achieve antibiotic concentrations above the MIC during 50 % and 100 % of the dosing interval. The use of intermittent infusion (compared to extended and continuous infusion) was the main determinant of non-attainment for both targets; increasing creatinine clearance was also associated with not attaining concentrations above the MIC for the whole dosing interval. In the light of this study from 68 ICUs across ten countries, we believe current empiric dosing recommendations for ICU patients are inadequate to effectively cover a broad range of susceptible organisms and need to be reconsidered.

Nur mit Berechtigung zugänglich

McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351CrossRefPubMed

Muller AE, Punt N, Mouton JW (2013) Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68:900–906CrossRefPubMed

Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730CrossRefPubMedCentralPubMed

Antonelli M, Bonten M, Cecconi M, Chastre J, Citerio G, Conti G, Curtis JR, Hedenstierna G, Joannidis M, Macrae D, Maggiore SM, Mancebo J, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2013) Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues. Intensive Care Med 39:345–364CrossRefPubMedCentralPubMed

Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39CrossRefPubMed

Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J (2010) Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 65:1771–1778CrossRefPubMed

van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJM (2005) Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 171:480–487CrossRefPubMed

Carlier M, Noe M, De Waele JJ, Stove V, Verstraete AG, Lipman J, Roberts JA (2013) Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother 68:2600–2608CrossRefPubMed

Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ (2013) Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17:R84CrossRefPubMedCentralPubMed

10.

Timsit JF, Citerio G, Bakker J, Bassetti M, Benoit D, Cecconi M, Curtis JR, Hernandez G, Herridge M, Jaber S, Joannidis M, Papazian L, Peters M, Singer P, Smith M, Soares M, Torres A, Vieillard-Baron A, Azoulay E (2014) Year in review in Intensive Care Medicine 2013: iii. sepsis, infections, respiratory diseases, pediatrics. Intensive Care Med 40:471–483CrossRefPubMed

11.

Carlier M, De Waele JJ (2013) Identifying patients at risk for augmented renal clearance in the ICU—limitations and challenges. Crit Care 17:130CrossRefPubMedCentralPubMed

12.

Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F (2013) Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 57:708–715CrossRefPubMedCentralPubMed

13.

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083CrossRefPubMed

14.

Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J (2012) DALI: defining antibiotic levels in intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 12:152CrossRefPubMedCentralPubMed

15.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829CrossRefPubMed

16.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710CrossRefPubMed

17.

Lipman J, Udy AA, Roberts JA (2011) Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 39:999–1000PubMed

18.

Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070–2082CrossRefPubMed

19.

Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44:357–363CrossRefPubMed

20.

Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB (2009) Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 34:429–433CrossRefPubMed

21.

Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP (2011) Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 37:632–638CrossRefPubMed

22.

Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J (2013) Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56:236–244CrossRefPubMed

23.

Kasiakou SK, Lawrence KR, Choulis N, Falagas ME (2005) Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 65:2499–2511CrossRefPubMed

24.

Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J (2007) Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30:11–18CrossRefPubMed

25.

Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML (2011) Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 11:181CrossRefPubMedCentralPubMed

26.

Grootaert V, Willems L, Debaveye Y, Meyfroidt G, Spriet I (2012) Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother 46:952–959CrossRefPubMed

27.

Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J (2014) Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 42:520–527CrossRefPubMed

28.

Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J (2010) Augmented creatinine clearance in traumatic brain injury. Anesth Analg 111:1505–1510CrossRefPubMed

29.

Udy AA, Putt MT, Boots RJ, Lipman J (2011) ARC–augmented renal clearance. Curr Pharm Biotechnol 12:2020–2029CrossRefPubMed

30.

Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J (2013) Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 17:R35CrossRefPubMedCentralPubMed

31.

Adnan S, Paterson DL, Lipman J, Kumar S, Li J, Rudd M, Roberts JA (2012) Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review. Surg Infect (Larchmt) 13:9–17CrossRef

32.

Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Vincent JL, Wallemacq P, Jacobs F (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126CrossRefPubMedCentralPubMed

33.

Goncalves-Pereira J, Paiva JA (2013) Dose modulation: a new concept of antibiotic therapy in the critically ill patient? J Crit Care 28:341–346CrossRefPubMed

34.

Gous AG, Dance MD, Lipman J, Luyt DK, Mathivha R, Scribante J (1995) Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 23:678–682PubMed

35.

De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J, Verstraete AG (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380–387CrossRefPubMed

36.

Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339CrossRefPubMed

37.

Scaglione F (2002) Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 19:349–353CrossRefPubMed

38.

Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, Durocher A, Roussel-Delvallez M (2010) Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 35:500–503CrossRefPubMed

39.

Connor MJJ, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH (2011) Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Antimicrob Agents Chemother 55:557–560CrossRefPubMedCentralPubMed

Titel: Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
verfasst von: Jan J. De Waele
J. Lipman
M. Akova
M. Bassetti
G. Dimopoulos
M. Kaukonen
D. Koulenti
C. Martin
P. Montravers
J. Rello
A. Rhodes
A. A. Udy
T. Starr
S. C. Wallis
J. A. Roberts
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Intensive Care Medicine / Ausgabe 9/2014
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-014-3403-8

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients